Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up  |  Already a member? Sign In  |  Visit IQPC.com  
Pharma IQ

EU Leaders Reach Agreement On Unitary Patent System

Contributor:  Pharma IQ News
Posted:  06/29/2012  12:00:00 AM EDT  | 
0

Rate this Article: (Be the First!)

- Comment from intellectual property specialists Marks & Clerk LLP –

Leaders of European Union states reached agreement today on a unitary patent system at a summit, settling on a compromise to share the location of the court between Paris, London, and Munich.

Keith Hodkinson, Partner and Chairman of Marks & Clerk International, comments:

“Today’s agreement does not in fact represent a final agreement on the Unitary Patent Court or a victory for the UK Government.

“Whilst the location the court is certainly of economic significance, and the decision to locate at least certain specialist work in London is of course welcome, the chief concern for the professions and industry has always been the fundamental flaws in the regime, rather than the issue of where cases are heard.

"Specifically, we have consistently opposed the provisions in articles six to eight governing the role of the European Court of Justice, a point evidently taken up by the UK Government in the horse trading which has gone on over the past few hours.

“Today’s agreement from the Council of Ministers "suggests" that these articles be deleted – indeed, this was the whole point of Cameron’s veto threat. But it is not at all clear that the Council of Ministers can insist on this or that the Commission will agree or what, if anything, would take the place of the deleted articles. It is quite possible that the UK has signed up to a blank cheque, or the very regime it was threatening to veto not more than a few hours ago.

"It is also unclear what will happen to the issue of bifurcation (splitting infringement and invalidity issues into separate proceedings).

“We would have preferred clarity on these fundamental practical issues in the regime before committing the UK to it. Better to allow a few months to rewrite the articles than to go into a new regime blind.

“So, despite talk of final agreement there are a number of pressing questions yet to be answered, and this process could yet continue for some time.”

Have Your Say
Rate this feature and give us your feedback in the comments section below


Pharma IQ News Contributor:   Pharma IQ News


* = required.

Not a member yet? Sign up
User Name:
Password:

Be the first to leave a comment
Sign in or Sign up to post a comment

Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Advertisement